Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. November 2013 16:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics Reports Financial Results for First Quarter of Fiscal Year 2014

SALT LAKE CITY, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for its fiscal first quarter ended Sept. 30, 2013. Revenue for the fiscal first...
29. Oktober 2013 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad myPlan(TM) Lung Cancer Test Launched to Leading Oncologists

SALT LAKE CITY, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has launched a new prognostic test, Myriad myPlan Lung Cancer, for patients diagnosed with...
28. Oktober 2013 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad myPlan(TM) Lung Cancer Test Meets Primary Endpoint in Validation Study

SALT LAKE CITY, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that validation data for the Myriad myPlan Lung Cancer test showed that it significantly predicted...
24. Oktober 2013 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad myRisk(TM) Hereditary Cancer Test Is Highly Accurate in Key Validation Study

SALT LAKE CITY, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data this week at the American Society of Human Genetics (ASHG) annual meeting in...
23. Oktober 2013 16:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics to Announce Fiscal First Quarter 2014 Financial Results on Tuesday November 5, 2013

SALT LAKE CITY, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the first fiscal quarter 2014 following the close of...
14. Oktober 2013 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad's myPath(TM) Melanoma Test is Highly Effective in Verification Study

SALT LAKE CITY, Oct. 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from a verification study showed the Myriad myPath™ Melanoma test effectively...
09. Oktober 2013 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics Study Highlights Importance of myRisk(TM) Hereditary Cancer Testing

SALT LAKE CITY, Oct. 9, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data showing the high prevalence and overlap between hereditary colon cancer and...
07. Oktober 2013 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad's myRisk Hereditary Cancer(TM) Test Improves Colon Cancer Testing by 60 Percent

SALT LAKE CITY, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new clinical data from a study with myRisk Hereditary Cancer, a 25-gene hereditary cancer panel,...
01. Oktober 2013 16:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics and BioMarin Advance PARP Collaboration Into Phase 3

SALT LAKE CITY, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that BioMarin Pharmaceutical Inc. will use Myriad's BRACAnalysis® test in connection with its...
25. September 2013 07:00 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics' myPlan(TM) Lung Cancer Test Meets Primary Clinical Endpoint

SALT LAKE CITY, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new data published in Clinical Cancer Research that showed the myPlan Lung Cancer test is a...

Vorherige Seite